Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30573% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Portfolio by asset class
Portfolio by asset class — U.S. Treasury & government agency debt securities ($M) ($M)
Moderna Portfolio by asset class: $66M in FY2025, down 52.2% from a year earlier.
Latest, FY2025
66
Period ended Dec 31, 2025
Change on a year earlier
-52.2%
138 in FY2024
History
6 years
Since FY2020
Sources
6
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-Q (filed 2026-07-31) ↗
Reported in Form 10-Q / 10-K Note 5 (Fair Value Hierarchy).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Portfolio by asset class — U.S. Treasury & government agency debt securities ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 66 | -52.2% | Form 10-Q (filed 2026-07-31) ↗ |
| FY2024 | Dec 31, 2024 | 138 | -33.7% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 208 | +49.6% | Form 10-K (filed 2025-02-21) ↗ |
| FY2022 | Dec 31, 2022 | 139 | +25.2% | Form 10-K (filed 2024-02-23) ↗ |
| FY2021 | Dec 31, 2021 | 111 | +753.8% | Form 10-K (filed 2023-02-24) ↗ |
| FY2020 | Dec 31, 2020 | 13 | – | Form 10-K (filed 2022-02-25) ↗ |
Cite this data
StockData. (2026). Moderna Portfolio by asset class ($M), annual FY2020–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/afs-us-gov-debt
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.